A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor

Conclusion.Pexidartinib combined with binimetinib was tolerable, and meaningful clinical activity was observed in two imatinib‐refractory patients.

Source: The Oncologist - October 15, 2019 Category: Cancer & Oncology Authors: Evan Rosenbaum, Ciara Kelly, Sandra P. D'Angelo, Mark A. Dickson, Mrinal Gounder, Mary L. Keohan, Suȷana Movva, Mercedes Condy, Travis Adamson, Chloe R. Mcfadyen, Christina R. Antonescu, Sinchun Hwang, Sam Singer, Li-Xuan Qin, William D. Tap, Ping Tags: Chinese Edition, Clinical Trial Results, Gastrointestinal Cancer Source Type: research